



Preliminary Program

Annual Meeting of the European Competence Network on Mastocytosis (ECNM). <http://ecnm.net/homepage/index.php>

Paris October 12-14, 2017

Imagine Institute

Scientific Committee

Michel Arock

Christine Bodemer-Skandalis

Olivier Hermine

Olivier Lortholary

Peter Valent

Local Committee

Michel Arock

Stéphane Barete

Christine Bodemer-Skandalis

Danièle Canioni

Gandhi Damaj

Olivier Hermine

Ludovic Lhermite

Olivier Lortholary

Anne-Florence Bellais

Company-driven Advisory Board

Wednesday October 11 – afternoon + evening: Company-Driven Advisory Boards

Thursday October 12 – morning: Company-Driven Advisory Boards

Thursday, October 12

13:30 Welcome Coffee

14:00 Michel Arock & Olivier Hermine (Paris, France)
Welcome Notes

14:10 Emir Hadzijusufovic (Vienna, Austria)
ECNM Homepage

14:20 Peter Valent (Vienna, Austria) & Michel Arock (Paris, France)
Status of the ECNM in 2017 and Plan until 2020

14:30 Michel Arock (Paris, France) & Peter Valent (Vienna, Austria)
Presentation of the Researcher of the Year 2017

14:40 Hanneke Kluin-Nelemans (Groningen, The Netherlands)
Development of interventional anti-neoplastic drug therapies in advanced mastocytosis

15:10 Coffee Break

15:30 Session I: Diagnostic Evaluation and Prognostication in SM-AHN
Chair: Peter Valent & Michel Arock

15:30 Luis Escribano & Alberto Orfao (Salamanca, Spain)
Diagnostic immunophenotyping in SM-AHN: markers and standards

15:50 Hans-Peter Horny (Munich, Germany)
Histologic and immunohistochemical standards in SM-AHN

16:10 Andreas Reiter (Mannheim, Germany)
Diagnostic molecular profiling and prognostication in SM-AHN

16:30 Coffee Break

16:50 Session II: Clinical Management and Therapeutic Approaches
Chairs: Olivier Hermine & Luis Escribano

16:50 Olivier Lortholary & Olivier Hermine (Paris, France)
Efficacy of masitinib in patients with severely symptomatic ISM

17:10 Mohamad Jawhar (Mannheim, Germany)
Response and resistance to midostaurin in advanced SM:
impact of molecular markers

17:30 Ivan Alvarez-Twose (Toledo, Spain)
Indications for imatinib in patients with mastocytosis

17:50 Jason Gotlib (Stanford, CA, USA)
Clinical research activity in advanced SM at Stanford

18:10 Michel Arock (Paris, France)
Preclinical studies with Blueprint compounds in mastocytosis

18:30 Mathias Schneeweiß (Vienna, Austria)
Preclinical studies with the Deciphera compound DCC-2618

18:50 Stéphane Barete (Paris, France)
Expression of CD30 in different categories of mastocytosis:
implication for prognosis and targeted therapy

20:00 Dinner

Friday, October 13

8:00 Welcome Coffee

8:30 Peter Valent (Vienna, Austria)
Overview of ECNM Registry Projects, Perspectives, and Publication Policies

8:45 Wolfgang R. Sperr (Vienna, Austria)
The ECNM Registry Projects: Technical and Contract Issues

9:00 Session IIIA: Presentation of First Wave Projects of the ECNM Registry **Chairs: Michel Arock & Massimo Triggiani**

9:00 Anja Illerhaus & Karin Hartmann (Cologne/Lübeck, Germany)
Age-adjusted diagnosis and prognostication in mastocytosis (PR1)

9:15 Marek Niedoszytko & Boguslaw Nedoszytko (Gdansk, Poland)
Impact of allergic disorders and anaphylaxis in mastocytosis (PR2)

9:30 Roberta Zanotti, Massimiliano Bonifacio & Patrizia Bonadonna (Verona, Italy)
Impact of bone marrow mastocytosis (BMM) (PR3)

9:45 Nadja Jäkel & Haifa Kathrin Al-Ali (Leipzig, Germany)
Clinical impact of serum tryptase levels in the FU in SM (PR4)

10:00 Anja Illerhaus & Hanneke Kluin-Nelemans (Cologne, Germany & Groningen, The Netherlands)
Clinical significance of blood count abnormalities in mastocytosis (PR5)

10:15 Juliana Schwaab & Andreas Reiter (Mannheim, Germany)
Impact of serum chemistry on diagnosis and treatment of SM (PR6)

10:30 Coffee Break

11:00 Massimo Triggiani (Salerno, Italy)
Spectrum of mediator-related symptoms in mastocytosis (PR7)

11:15 Luca Malcovati, Chiara Elena & Serena Merante (Pavia, Italy)
Treatment of patients with mastocytosis: outcomes & response rates (PR8)

11:30 Agnes Bretterkieber (Graz, Austria)
Skin lesions in different categories of mastocytosis (PR9)

11:45 Wolfgang R. Sperr (Vienna, Austria)
Proposed IPSS for patients with mastocytosis (PR10)

12:00 David Fuchs (Linz, Austria)
Risk of SM in patients with MIS (PR11)

12:15 Lunch Break

13:20 Session IIIB: Presentation of Second Wave Projects of the ECNM Registry
Chairs: Wolfgang R. Sperr & Hanneke Kluin-Nelemans

13:40 Anja Illerhaus & Karin Hartmann (Cologne/Lübeck, Germany)
Characterization and prognosis of patients with smouldering SM (SSM) (PR12)

14:00 Mohamad Jawhar & Andreas Reiter (Mannheim, Germany)
Clinical impact of organomegaly in patients with systemic mastocytosis (PR13)

14:20 Aleksandra Gorska & Magdalena Lange (Gdansk, Poland)
Impact of the body mass index in patients with mastocytosis (PR14)

14:40 Khalid Shoumariyeh & Nikolas von Bubnoff (Freiburg, Germany)
Clinical features and course of patients with various forms of ASM (PR15)

15:00 Coffee Break

15:20 Jason Gotlib (Stanford, USA)
Clinical course of patients with diverse variants of MCL (PR16)

15:40 Michael Doubek (Brno, Czech Republic)
Features, course, and prognosis of typical ISM (excluding BMM/SSM) (PR17)

16:00 General Discussion

16:20 Session IIIC: Presentation of Potential New ECNM Registry Projects (3rd Wave)
Chairs: Peter Valent & Karin Hartmann

16:20 Knut Brockow (Munich, Germany)
Pure cutaneous mastocytosis in adults: clinical features and course (PR18)

16:40 Olivier Hermine (Paris, France)
AHN: frequency, distribution, sub-types, and prognostic impact (PR19)

17:00 Akim Selim Yavuz (Istanbul, Turkey)
Bone lesions and related symptoms in mastocytosis (PR20)

17:20 Vito Sabato (Antwerpen, Belgium)
Prognostic impact of percent mast cells in BM smears vs BM histologies (PR21)

17:40 Peter Vandenberghe (Leuven, Belgium)
Diagnostic and prognostic impact of cytogenetics in SM (PR22)

- 18:00 Deborah Christen & Jens Panse (Aachen, Germany)
Prognostic impact of platelet counts in SM and comparison to hemoglobin and ANC counts (PR23)
- 18:20 Closed registry steering committee session: discussion, nomination, selection, and approval of new ECNM registry projects
- 20:00 Gala Dinner**

Saturday, October 14

8:00 Welcome Coffee

8:30 Session IV: Basic Science, Pathology, and Molecular Markers

Chair: Alberto Orfao & Cem Akin

8:30 Karl Sotlar (Munich, Germany)
Updated WHO classification of mast cell disorders

8:50 Tracy George (Albuquerque, NM, USA)
Clinicopathologic features of mast cell leukemia

9:10 Lawrence B. Schwartz (Richmond, VA, USA)
Tryptase as diagnostic parameter in daily practice

9:30 Dean D. Metcalfe (Bethesda, MD, USA)
Mast cell growth and activation: from understanding mechanisms to therapy

9:50 Coffee Break

10:10 Session V: Anaphylaxis and mastocytosis

Chair: Dean D. Metcalfe & Knut Brockow

10:30 Hanneke Oude Elberink (Groningen, The Netherlands)
Allergy and mastocytosis: risk evaluation and management

10:50 Patrizia Bonadonna (Verona, Italy)
News in Hymenoptera venom allergy and mastocytosis

11:10 Cem Akin (Ann Arbor, MI, USA)
Diagnosis and management of MCAS: update 2017

11:30 Coffee Break

12:00 Session VI: Hot Topics and Late Breaking Abstracts

Chair: Olivier Lortholary & Lawrence B. Schwartz

12:00 Mohamad Jawhar & Andreas Reiter (Mannheim, Germany)
"MCL and SM-AML: experiences from a single institution"

12:15 Sigurd Broesby-Olsen (Odense, Denmark)
Diagnostic algorithm in suspected mastocytosis: the Nordic experience

- 12:30 Gunnar Nilsson (Stockholm, Sweden)
Single cell analysis of *KIT* D816V mutation during hematopoiesis
- 12:45 Flavia Guillem (Paris, France)
Effects of XPO1 antagonists on *KIT* D816V+ neoplastic MCs
- 13:00 Laura Polivka (Paris, France)
Genetic insights into the familial forms of mastocytosis
- 13:15 Mariana Castells (Boston, MA, USA)
Ultra rush desensitization for hymenoptera anaphylaxis in Mastocytosis:
the Next Generation
- 13:30 Melody Carter (Bethesda, MD, USA)
Pediatric mastocytosis: diagnosis & management
- 13:45 Stéphane Barete (Paris, France)
Improvement of cutaneous mastocytosis: place for topical and systemic treatments
- 14:00 Summary and Concluding Remarks**
Olivier Hermine, Peter Valent & Michel Arock